Company Valuation: Interpace Biosciences, Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2020 2021 2022 2023 2024 2025
Market Cap 1 12.69 31.18 4.437 4.693 11.87 5.448
Change - 145.72% -85.77% 5.76% 152.98% -54.11%
Enterprise Value (EV) 1 14.8 41.84 15.7 12.39 16.27 4.126
Change - 182.66% -62.47% -21.1% 31.32% -74.64%
P/E -0.43x -2.06x -0.2x 6.03x 6.84x 1.39x
PBR -0.44x -0.74x -0.07x -0.08x -5.36x 0.25x
PEG - 0x -0x -0x 0x 0x
Capitalization / Revenue 0.39x 0.75x 0.14x 0.12x 0.25x 0.14x
EV / Revenue 0.46x 1.01x 0.49x 0.31x 0.35x 0.11x
EV / EBITDA -0.7x -6.28x -12.3x 3.23x 1.93x 0.79x
EV / EBIT -0.56x -3.56x -4.09x 4.41x 2.01x 0.86x
EV / FCF -2.21x -25.8x -15.1x 2.93x 11.5x 0.81x
FCF Yield -45.2% -3.87% -6.64% 34.1% 8.66% 123%
Dividend per Share 2 - - - - - -
Rate of return - - - - - -
EPS 2 -36.61 -18.09 -25.91 0.8948 1.972 4.426
Distribution rate - - - - - -
Net sales 1 32.4 41.31 31.84 40.21 46.93 38.73
EBITDA 1 -21.15 -6.663 -1.28 3.837 8.408 5.209
EBIT 1 -26.56 -11.74 -3.84 2.811 8.108 4.784
Net income 1 -26.45 -14.94 -21.96 0.802 6.702 24.58
Net Debt 1 2.11 10.65 11.26 7.694 4.395 -1.322
Reference price 2 15.700 37.350 5.200 5.400 13.488 6.151
Nbr of stocks (in thousands) 808 835 853 869 880 886
Announcement Date 4/1/21 3/31/22 3/27/23 4/1/24 3/31/25 3/30/26
1USD in Million2USD
Estimates


P/E (N) EV / Sales (N) EV / EBITDA (N) Dividend Yield (N) Capi.($)
- - - - 35.41M
12.47x0.39x8.09x3.1% 110B
14.42x1.81x9.05x0.73% 92.39B
-296.28x20.11x-348x-.--% 59.58B
13.66x1.5x9.02x2.61% 28.62B
22.94x2.56x12.99x1.42% 25.72B
22.11x2.04x11.71x0.95% 24.99B
31.17x5.62x23.35x2.24% 21.11B
7.76x1.41x6.4x-.--% 20.58B
30.61x2.86x12.89x1.47% 16.95B
Average -15.68x 4.26x -28.28x 1.39% 39.96B
Weighted average by Cap. -30.24x 4.41x -43.25x 1.54%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA


  1. Stock Market
  2. Stocks
  3. IDXG Stock
  4. Valuation Interpace Biosciences, Inc.